FDA updates ‘box warning’ for Arzerra and Rituxan to include Hepatitis B reactivation risk

The US Food and Drug Administration (FDA) announced Wednesday the approval of changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to More...